Uppsala University Hospital
Uppsala, Sweden
NCT Number: NCT07346950
This observational study aims to compare disease burden and pain characteristics between fibromyalgia patients with high levels of autoreactive autoantibodies, fibromyalgia patients with low levels of autoreactive autoantibodies, and healthy controls. The primary hypothesis is that patients experience more symptoms (as measured with questionnaires) depending on their antibody titer, and that high levels of autoantibodies correlate with other biological markers, such as inflammatory profile in serum, and density of intraepidermal nerve fibers in skin.
The secondary aim of this study is to characterize central markers of disease, which will be done using a number of methods: the investigators will quantify immune profile in the cerebrospinal fluid, measure thalamic neurotransmitter levels with magnetic resonance spectroscopy (MRS), blood-brain barrier permeability with both biochemical markers and T1-weighed gadolinium-enhanced magnetic resonance imaging (MRI), and resting state activity of the brain (MRI). The investigators hypothesize that there are signs of upregulation of the immune system of the central compartment, and that this will be correlated with altered neurotransmitter levels and an altered resting state activity.
Looking for future studies?
Notify Me20 year–70 year
Female
Observational
Uppsala, Sweden
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: At study inclusion.
Autoantibodies that bind to satellite glia cells in the dorsal root ganglia. The investigators hypothesize that autoantibody titers are associated with symptom severity (Goebel et al., 2021; Krock et al., 2023; Fanton et al., 2023), changes in inflammatory profile (af Ekenstam et al., 2025) and alterations in skin histological findings.
Time frame: At study inclusion.
Using magnetic resonance spectroscopy, the first 55 FM subjects and the first 25 HC subjects had their levels of neurotransmitters in the right thalamus quantified. The investigators hypothesize that FM patients will have upregulated glutamate levels in their thalamus, and that glutamate levels will be associated with restless legs symptom severity.
Time frame: At study inclusion.
Using multiplexed proximity-extension assays (OLINK, Uppsala, Sweden), the investigators aim to quantify the levels of cytokines and chemokines in the serum of patients with fibromyalgia and in healthy, pain-free controls. FM patients are hypothesized to have an upregulation of cytokines related to B-cell activity, such as CD40 (af Ekenstam et al., 2025).
Time frame: At study inclusion.
Using multiplexed proximity-extension assays, the investigators aim to quantify the levels of cytokines and chemokines in the cerebrospinal fluid of patients with fibromyalgia and in control samples from patients that underwent a neurological work-up at the neurological clinic of Uppsala University Hospital. The investigators hypothesize that fibromyalgia patients have upregulated cytokine levels in CSF (Rosenström et al., 2024a), especially regarding e.g. fractalkine, IL8, CCL19, CCL25 - which have previously been found to be upregulated (Bäckryd et al., 2017) and separately been associated with glia cell activity (Maciejewski-Lenoir et al., 1999), BBB permeability (García-Fernández et al., 2023) and fatigue (Rosenström et al., 2025).
Time frame: At study inclusion.
The CSF/serum albumin quotient is the gold standard for quantification of blood-brain barrier integrity. The investigators hypothesize that (female) FM patients will have a more permeable BBB, i.e., higher CSF/serum albumin quotient than (female) patients with lumbar disc herniation, degenerative disc disease, osteoarthritis or control patients, suggesting an increased peripheral-central communication, which in turn has been reported to be important for the central immunoenvironment (Rosenström et al., 2025).
Time frame: At study inclusion.
QST was used to measure pressure pain thresholds (PPTs), temporal summation and conditioned pain modulation in all FM and HC subjects. FM are expected to have lower PPTs, a stronger temporal summation and impaired descending inhibition compared to HC (Kosek & Hansson, 1997).
Time frame: At study inclusion.
All FM and HC participants gave two 4mm punch biopsies of the skin from their right thigh (lateral). These samples will be used to quantify IENFD to be used as a correlation measure with autoantibody titers and inflammatory profiles in serum. The investigators expect reduced IENFD in patients with fibromyalgia (Üçeyler et al., 2013; Evdokimov et al., 2019), and hypothesize that IENFD will be correlated with autoantibody titers.
Time frame: At study inclusion.
All FM and HC subjects underwent a one-night ambulatory polysomnography to characterize their sleep quality objectively. The investigators hypothesize that fibromyalgia patients have disturbed overall sleep quality (Muza et al., 2023).
Time frame: At study inclusion.
Using rsfMRI, the resting state activity of the brain will be measured in the first 55 FM subjects and in the first 25 HC subjects. We expect a higher functional connectivity in areas related to the default network and lower functional connectivity in areas related to endogenous pain modulation (Cavicchioli et al., 2025).
Time frame: At study inclusion.
Using a gadolinium-enhanced, T1-weighted MRI method, the investigators will assess the dynamic permeability of the BBB in the brain of the first 55 FM subjects and the first 25 HC subjects. The investigators hypothesize that FM patients will have a more leaky BBB than controls, as indicated by a faster uptake of gadolinium in the CSF and brain parenchyme. This will be quantified by MRI physicists using standard quantification metrics that mirror physiological function.
Uppsala University
Other
Acronym: FINE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04263454
Chronic Pain, Fibromyalgia
Birmingham, Alabama, United States
View Trial DetailsNCT06574165
Behavior, Chronic Pain
Birmingham, Alabama, United States
View Trial DetailsNCT05998369
Abdominal Pain, Autonomic Nervous System Diseases
Palo Alto, California, United States
View Trial DetailsNCT06752590
Fibromyalgia, Muscular Diseases
Nagakute, Aichi-ken, Japan
View Trial Details